Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis: Histologically confirmed Hodgkins lymphoma~* Relapsed or refractory disease after at least two prior lines of treatment~* Age 18-70 years old~* Signed informed consent~* No severe concurrent illness~Exclusion Criteria:~* Uncontrolled bacterial or fungal infection at the time of enrollment~* Requirement for vasopressor support at the time of enrollment~* Karnofsky index \<30%~* Pregnancy~* Somatic or psychiatric disorder making the patient unable to sign informed consent~* Active or prior documented autoimmune disease requiring systemic treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nivolumab 40 mg (Type: EXPERIMENTAL): Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).